BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Skyrizi (risankizumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Skyrizi (risankizumab)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07466550-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Skyrizi (risankizumab): Phase 1 readout est. (NCT07466550)
DESCRIPTION:Skyrizi (risankizumab)\, phase 1.\nStudy: A Study to Assess How
  Intravenous and Subcutaneous Administrations of Risankizumab Moves Throug
 h the Body of Healthy Adult Participants\nEstimated primary completion: Ja
 nuary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/risankizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07466550
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06063967-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT06063967)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: A S
 tudy to Assess Adverse Events and Change in Disease Activity of Risankizum
 ab Subcutaneous Induction Treatment for Moderately to Severely Active Croh
 n's Disease.\nEstimated primary completion: March 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06063967
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880744-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT06880744)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Ulcerative Colitis.\nStudy: 
 A Study to Assess the Change in Disease Activity in Adult Participants Wit
 h Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared
  to Vedolizumab\nEstimated primary completion: August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06880744
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07258641-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Skyrizi (risankizumab): Phase 1/2 readout est. (NCT07258641)
DESCRIPTION:Skyrizi (risankizumab)\, phase 1/2\, Ulcerative Colitis.\nStudy
 : Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Infla
 mmatory Bowel Disease\nEstimated primary completion: 31 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07258641
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138898-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Skyrizi (risankizumab): Phase 2 readout est. (NCT07138898)
DESCRIPTION:Skyrizi (risankizumab)\, phase 2.\nStudy: Immunosuppressant Man
 agement in Rheumatology Patients Undergoing Elective Total Shoulder Arthro
 plasty\nEstimated primary completion: January 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07138898
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04524611-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT04524611)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: Stu
 dy Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Uste
 kinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult
  Participants With Moderate to Severe Crohn's Disease (CD)\nEstimated prim
 ary completion: February 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/risankizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04524611
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862286-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT04862286)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Psoriasis.\nStudy: Study to 
 Evaluate Adverse Events and Change in Disease Activity in Participants Bet
 ween 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With 
 Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participati
 on in Study M19-977\nEstimated primary completion: April 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04862286
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07177118-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20280620
DTEND;VALUE=DATE:20280621
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT07177118)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Ulcerative Colitis.\nStudy: 
 Risankizumab for Fibrostenotic Crohn's Disease Treatment\nEstimated primar
 y completion: 20 June 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/risankizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07177118
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03398135-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT03398135)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Ulcerative Colitis.\nStudy: 
 A Study to Assess the Efficacy and Safety of Risankizumab in Participants 
 With Ulcerative Colitis\nEstimated primary completion: September 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03398135
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07872449-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Skyrizi (risankizumab): Phase 4 readout est. (NCT07872449)
DESCRIPTION:Skyrizi (risankizumab)\, phase 4\, Crohn's Disease.\nStudy: Ris
 ankizumab for Refractory Perianal Fistulizing Crohn's Disease\nEstimated p
 rimary completion: 13 October 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/risankizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07872449
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07499232-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20281115
DTEND;VALUE=DATE:20281116
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT07499232)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: A S
 tudy of Guselkumab Versus Risankizumab in Participants With Moderately to 
 Severely Active Crohn's Disease\nEstimated primary completion: 15 November
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/risankizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07499
 232
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03105102-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT03105102)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: A S
 tudy of the Efficacy and Safety of Risankizumab in Participants With Crohn
 's Disease\nEstimated primary completion: February 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03105102
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05995353-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT05995353)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: A S
 tudy to Assess Adverse Events\, Change in Disease Activity\, and How Intra
 venous and Subcutaneous Risankizumab Moves Through the Body of Pediatric P
 articipants With Moderately to Severely Active Crohn's Disease\nEstimated 
 primary completion: April 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/risankizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05995353
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865105-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Skyrizi (risankizumab): Phase 2 readout est. (NCT06865105)
DESCRIPTION:Skyrizi (risankizumab)\, phase 2\, Psoriatic Arthritis.\nStudy:
  Study of Targeted Therapies for the Treatment of Adult Participants With 
 Active Psoriatic Arthritis\nEstimated primary completion: August 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06865105
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548542-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Skyrizi (risankizumab): Phase 2 readout est. (NCT06548542)
DESCRIPTION:Skyrizi (risankizumab)\, phase 2\, Crohn's Disease.\nStudy: Stu
 dy of Targeted Therapies for the Treatment of Adult Participants With Mode
 rate to Severe Crohn's Disease\nEstimated primary completion: January 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06548542
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Skyrizi (risankizumab): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Skyrizi (risankizumab)\, phase 4\, Psoriasis.\nStudy: Utilizati
 on of a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated primary
  completion: 1 June 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/risankizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07352566
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07697456-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Skyrizi (risankizumab): Phase 2 readout est. (NCT07697456)
DESCRIPTION:Skyrizi (risankizumab)\, phase 2\, Ulcerative Colitis.\nStudy: 
 Study of Advanced Therapies for the Treatment of Adult Participants With M
 oderately to Severely Active Crohn's Disease or Ulcerative Colitis\nEstima
 ted primary completion: October 2031. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/risankizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07697456
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071519-3@assetmemo.bio
DTSTAMP:20261121T005632Z
DTSTART;VALUE=DATE:20340731
DTEND;VALUE=DATE:20340801
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT07071519)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Ulcerative Colitis.\nStudy: 
 A Study to Learn More About How Risankizumab Works in Young Participants W
 ith Ulcerative Colitis\nEstimated primary completion: July 2034. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07071519
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
